Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$130.67 USD

130.67
1,327,706

+2.92 (2.29%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $130.73 +0.06 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

NextGen's (NXGN) fiscal fourth-quarter 2020 results gain from strong Recurring revenues.

Zacks Equity Research

Cooper Companies (COO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.

Zacks Equity Research

FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid

by Zacks Equity Research

With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.

Zacks Equity Research

Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.

Zacks Equity Research

Bristol-Myers (BMY) Wins EC Approval for MS Drug Zeposia

by Zacks Equity Research

Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis.

Zacks Equity Research

Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Sheraz Mian headshot

Top Analyst Reports for Alibaba, Chevron & Shopify

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Chevron (CVX) and Shopify (SHOP).

Zacks.com headshot

Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks.com

Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.

Zacks Equity Research

McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.

Zacks Equity Research

Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy

by Zacks Equity Research

Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy

Sumit Singh headshot

Coronavirus Ruining Portfolio? Bet on These 4 Low P/CF Stocks

by Sumit Singh

Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.

Zacks Equity Research

Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA

by Zacks Equity Research

Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.

Kinjel Shah headshot

4 Low Price-to-Book Value Stocks to Buy in May

by Kinjel Shah

Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.

Zacks Equity Research

STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.

Zacks Equity Research

GNC Holdings' (GNC) Q1 Earnings and Sales Miss Estimates

by Zacks Equity Research

All the operating segments of GNC Holdings (GNC) register significant year-over-year sales decline in Q1 on coronavirus-led business disruption.

Zacks Equity Research

AMN Healthcare (AMN) Q1 Earnings In Line With Estimates

by Zacks Equity Research

AMN Healthcare (AMN) gained from core operating segments in Q1.

Zacks Equity Research

Sanofi's Blood Disorder Candidate Gets FDA's Priority Review

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).

Zacks Equity Research

Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss

by Zacks Equity Research

Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

Zacks Equity Research

Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines

by Zacks Equity Research

Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.

Zacks Equity Research

HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.

Zacks Equity Research

Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.

Zacks Equity Research

National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls

by Zacks Equity Research

National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.

Zacks Equity Research

Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.

Zacks Equity Research

Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.

Zacks Equity Research

Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline

by Zacks Equity Research

Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.